DisEMBARK? FDA Questions Accelerated Approval Impact On Sarepta’s Fully Enrolled Clinical Trial

 
• By Sue Sutter
  
Gangplank
US FDA questions whether US study subjects will leave the EMBARK trial if SRP-9001 receives accelerated approval. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers